NZ554904A - In-situ forming implant for animals - Google Patents

Abstract

Provided is a composition for forming a solid implant in situ within a body by exposure to body fluids, suitable for a controlled release of bioactive material, comprising (i) a biologically active agent, (ii) 10 to 25% by weight of the total composition of a pharmaceutically acceptable, biodegradable, thermoplastic polymer, which is a polylactide which is insoluble in aqueous media or human or animal body fluids, (iii) 50 to 80% by weight of the total composition of a pharmaceutically acceptable, biodegradable, water-insoluble or slightly water-soluble organic solvent, which is a triester of glycerin, and (iv) above 0 to up to 10% by weight of the total composition a pharmaceutically acceptable, water-soluble and biocompatible adjuvant selected from the group consisting of C2-C6alkanols, polyhydroxy alcohols and ketals. Further provided are implants made of said composition and a method of implanting the implant in a non-human animal body.

Description

New Zealand Paient Spedficaiion for Paient Number 554904 554904 IN-SITU FORMING IMPLANT FOR ANIMALS Many attempts have been made for developing galenic formulations, applicable as slow-release carriers in drug delivery. Most often these slow-release carriers are polymers, usually made of thermoplastic resins, which liquefy or soften upon heating and re-solidify upon cooling, are generally formed into the desired structure according to their use, e. g. as surgical clips, staples or implants, prior to insertion into the body. Once inserted, they retain their shape.

Surprisingly, only few of these slow-release systems, e. g. Profact®, Zoladex® and Atridox®, reached the commercial stage seemingly indicating that the known slow-release carriers show undesired side effects hampering commercialization.

When used as drug delivery devices, the drug is incorporated within the polymeric composition and the shape of the device is formed outside the body. This solid implant is then typically inserted into the body of a human or animal through an incision. Certain polymers can be injected via a syringe as a liquid composition. Biodegradable liquid polymeric compositions applicable for slow-release drug delivery systems are described, e. g. in U. S. pat. no. 5,702,716 and U. S. pat. no. 4,938,763. These polymeric compositions are administered into the body in a liquid state or, alternatively, as a solution, typically by means of a syringe. In the body the composition coagulates or cures into a solid. One type of polymeric composition consists of a non-reactive thermoplastic polymer or co-polymer dissolved in a water-miscible solvent. This polymeric solution is placed into the body where the polymer congeals or solidifies upon dissipation or diffusion of the solvent into the surrounding body tissue.

The presence of a plasticizer within a sustained release composition is known to advance the release of bioactive material by the polymer. Known plasticizers have been used to enhance the delivery of drugs from slow-release delivery systems, e. g. described by K. Juni in Chem. Pharm. Bull. 33, 1609 (1985) and by Wong et al. in U. S. pat. no. 4,127,127. While water-insoluble liquid plasticizers are used to soften the polymer or co-polymer, increasing the diffusion coefficient for non-ionic drugs, water-soluble plasticizers are applied, if the goal is to create a microporous structure of the polymeric composition, caused by their slow leaching from the polymer resin upon exposition to an aqueous environment, thus making the composition more permeable for drugs. 554904 Although the known liquid polymeric compositions have shown their advantages in the use for sustained drug release in medical applications, their release rates are usually slightly controllable and generally too high. Normally, minutes or hours after the implantation of the composition an undesired peak of the bioactive agent in the blood level is observed, followed by the targeted slow release over time. This peak is potentially harmful as it can lead to overdosing and toxic effects. Beyond this, the overall time for a release of an effective amount of drugs is shortened. Hence, there is a need for a liquid polymeric composition, which allows the control of the drug delivery over a defined, preferably long, period.

Surprisingly, the release and biodegradation properties of a polymer-based slow-release system can be significantly improved if the polymeric composition contains, besides a micro-porous, solid matrix of a thermoplastic polymer and a bioactive material, a large excess of a third component, which not only serves as a solvent for the thermoplastic polymer but also acts as a rate modifying agent controlling the release rate of the bioactive material. In the following this third component will nevertheless be referred to as solvent.

An object of the present invention is to provide an accordingly improved composition for a slow-release drug delivery system that can be administered in liquid form into the body.

A further object is to provide an according composition which forms a solid matrix within the body after administration in liquid form, able to release a drug over a desired period of time.

Yet another object is to provide an according composition which allows the control of the amount and rate of the drug delivery over a preferably long term.

These objects should be read disjunctively with the object of at least providing a useful alternative to known compositions.

Hence, the invention is directed to a polymeric system, a method for therapeutic treatment using the polymeric system and the precursor of the polymeric system, a liquid composition.

The present invention is, in the first instance, directed to a composition for forming a solid implant in situ within a body by exposure to body fluids, suitable for a controlled release of bioactive material, comprising (i) a biologically active agent; (ii) 10 to 25% by weight of the total composition of a pharmaceutically acceptable, biodegradable, thermoplastic polymer, which is a polylactide which is insoluble in aqueous media or human or animal body fluids, intellectual property QFFlCr OF N-A 21 OCT 2009 received 554904 (iii) 50 to 80% by weight of the total composition of a pharmaceutical^ acceptable, biodegradable, water-insoluble or slightly water-soluble organic solvent, which is a trimester of glycerin, and (iv) above 0 to up to 10% by weight of the total composition of a pharmaceutical^ acceptable, water-soluble and biocompatible adjuvant selected from the group consisting of C2-C6alkanols, polyhydroxy alcohols and ketals.

The polymeric system of the present invention coagulates to a solid in-situ matrix upon application of the liquid composition to the aqueous medium of the body fluids, where it is essentially insoluble, while the organic solvent gradually diffuses into the surrounding body fluids. The coagulation process is responsible for the development of the rate and release control and varies as a function of the parameters and components mentioned below. Simple combination of the components without passing the stage of the liquid composition does not result in the controlled release profile of the present invention.

The essentially simultaneous diffusion and coagulation process creates the microporous structure of the matrix which is believed to be responsible for the control of the rate and extent of drug release. Under the conditions of the invention, the matrix structure exhibits a core containing large pores, enclosed by a relatively nonporous skin with very small pores. The resulting solid matrix adopts the shape of the cavity within the body into which the composition is placed.

During the process of the polymeric system coagulating to a solid in-situ matrix, the rate of release of the bioactive substance is generally temporarily increased until after the end of the coagulation process, which is expressed as an initial peak during the progression of the blood level of the bioactive agent after application. This may be explained by the fact that said nonporous skin, which is essentially responsible for the steady slow release of the bioactive agent, only just forms in the initial phase of the coagulation process and, thus, the rate of release is at first controlled by the porous structure of the gradually coagulating core of the liquid polymeric system immediately after its application into the body. This temporary peak in the release rate can cause a momentary overdose of the bioactive compound, which is undesired and in some cases might be harmful. The amount in height and time of the initial peak release rate is a function of the concentration of the bioactive material in the polymeric system, the viscosity of the latter and the concentration and kind of adjuvants at the time of application. 21 oct 2009 I R E C EI v t ~J \ 554904 It has been surprisingly found out that substitution of up to 10% of the solvent by an organic, water-soluble adjuvant to the liquid composition has a decidedly decreasing effect on the initial peak of the blood level of the bioactive agent immediately after application.

The present invention provides a composition which effectively suppresses the initial peak release rate after the application of the liquid polymeric system into the body of a human or animal in that said composition additionally encompasses an organic, water-soluble adjuvant.

The long-term in-situ rate and extent of the drug release of the matrix - i. e. after the initial peak release rate - can be controlled by the variation of the parameters and conditions of the invention. This control can be accomplished by a) variation of polymer type and molecular weight, b) the concentration of the polymer, c) the water-solubility properties of the organic solvent, d) the concentration of the organic solvent, e) the concentration of the bioactive material, f) the form of the bioactive material, g) further adjuvants and h) the concentration of the adjuvants present within the matrix.

Preferably, within the scope of the invention the rate and extent of the drug release is controlled by the variation of the organic solvent and its concentration, the concentration of the bioactive material, the presence or absence of further adjuvants and their concentration.

More preferably, the rate and extent of the drug release is controlled by the variation of the organic solvent and the presence or absence of further adjuvants.

Most preferably, the rate and extent of the drug release is controlled by the variation of the parameters and conditions given in the examples below.

The method of the invention is based upon the blood level measurement of the in-situ controlled release of the bioactive material from the polymer system. The implantation of the liquid composition can generally occur anywhere within the body of a human or animal. Examples include soft tissue such as muscle or fat, or the subcutaneous tissue. The liquid composition can be administered by any suitable method, as for example by means of a syringe needle. intellectual property (foll6$/§Q!by^ag4 4a) 21 oct 2mb received 554904 - 4a - The polymer system is prepared by combining the liquid composition and an aqueous medium, such as the body fluids, to coagulate the composition into a solid, microporous, polymeric matrix. The liquid composition contains a biocompatible, thermoplastic polymer or co-polymer in combination with a biocompatible, organic solvent and optionally a biocompatible adjuvant. The thermoplastic polymer or co-polymer is biodegradable and/or bioerodible within the body of the human or animal. The biodegradability enables the body to metabolize the polymer matrix allowing it to excrete it without the need for surgery to remove it. Selection of biocompatible material makes sure that the insertion process and the presence of the polymer system within the body do not cause substantial tissue irritation or necrosis at the site of the implant.

[FOLLOWED BY PAGE 5] 554904 PC I7F.P2005/013377 Suitable thermoplastic polymers or co-polymers for the incorporation as the solid matrix of the controlled release system include polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyester amides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid) polymers, polymaleic anhydrides, poly(methylvinyl) ethers, poly(amino acids), chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials.

Preferred materials are polylactides, in particular polylactic acid, glycolic acid and copolymers thereof, most particularly polylactic acid. These polymers show excellent biocompatibility, as they produce little, if any, tissue irritation, inflammation, necrosis, or toxicity. In the presence of water, these polymers degrade to lactic and glycolic acid, respectively, which are readily metabolized in the body.

The concentration of the thermoplastic polymer in the liquid composition lies in the range of about 10% to about 25%, preferably in the range of about 15% to about 20% of the total weight of the composition.

According to the practice of the invention, the liquid composition containing the thermoplastic polymer, organic solvent, bioactive material and potentially adjuvant is a stable liquid substance. Depending on the bioactive material and solvent chosen, either a homogeneous solution or a suspension or dispersion of the bioactive material in the liquid composition results. In either case, the thermoplastic polymer is substantially soluble in the liquid composition. Upon placement of the liquid composition into the aqueous medium inside the body, the polymer will solidify to form the polymer system carrying within a solid matrix the bioactive material and a decreasing amount of the gradually diffusing organic solvent, which acts as rate-modifying agent.

The adjuvants optionally used in the thermoplastic compositions of the invention are preferably pharmaceutical^ acceptable, water-miscible and biocompatible. Preferably, they cause relatively little, if any, tissue irritation or necrosis at the site of the injection. The solvent is water-miscible to allow it to quickly dissipate from the polymeric composition into the aqueous body fluids, concomitantly accelerating the formation of the nonporous skin and hence suppressing the initial peak release rate of the drug after the application.

Examples of suitable adjuvants encompass N-methyl-2-pyrrolidone, 2-pyrroIidone, C2-C6alkanols, 2-ethoxyethanol, polyhydroxy alcohols such as propylene glycol, polyethylene 554904 P(IVI.P2005/013377 glycol, glycerol or sorbitol, alkyl esters such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, propylene carbonate or ethyl lactate, ethylene glycol dimethyl ether, propylene glycol, alkyl ketones such as acetone or methyl ethyl ketone, ketals such as glycerol formal, dimethylformamide, dimethyl sulfoxide, dimethyl sulfone, tetrahydrofuran, and cyclic alkyl amides such as caproiactam. The preferred adjuvants are C2-C6alkanols, polyhydroxy alcohols or ketals, in particular ethanol, glycerol or glycerol formal.

The water-soluble or slightly water-soluble, organic solvents used in the present invention are known to control the sustained release character of the polymer system. The combination of a suitable solvent and a matrix formed by an aggregation process as outlined above has a significantly retarding effect on the release rate of the bioactive material in comparison with a matrix without a corresponding solvent. The retarding effect can lie in the range of several orders of magnitude, depending on the structure and amount of the rate-modifying solvent. Thus, by the appropriate choice of the thermoplastic polymer or copolymer, combined with a suitable solvent, the rate and extent of release of bioactive material from the polymer system can deliberately be varied from very fast to very slow.

Solvents acting as rate modifying agents in the present invention are liquids which dissolve the thermoplastic polymer and are preferably water-insoluble or slightly water-soluble. They also preferably have a high boiling point. The ideal rate-modifying solvent imparts to the finally coagulated polymer matrix a glass transition temperature at about the temperature of the human or animal body or below, ensuring a soft, resilient and flexible implant.

The solvents used in the present invention are pharmaceutical^ acceptable. Specific examples encompass esters of mono-, di- and tricarboxylic acids such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, diethyl phthalate, dimethyl phthalate, dibutyl phthalate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate or di(n-butyl) sebacate; fatty acids; triesters of glycerol such as glycerol triacetate (triacetin), epoxidized soybean oil and other epoxidized vegetable oils; sterols such as cholesterol; alcohols such as CB-Ci2 alkanols; and mixtures thereof, Preferred solvents are triesters of glycerol, in particular glycerol triacetate (triacetin).

The amount of the rate modifying solvent in the thermoplastic composition preferably exceeds that of the polymer, more preferably it lies in the range of about 50% to about 80%, most preferably in the range of about 55% to about 66% of the total weight of the composition. 554904 The term "drug", "bioactive material" or "biologically active agent" as used herein encompasses biologically, physiologically or pharmacologically active substances that act locally or systemically in the human or animal body. The bioactive material can be applied in various forms which are capable of being released from the polymer system into the adjacent body tissues or fluids. Due to the high amount of organic, rate-modifying solvent in the thermoplastic composition of this invention the bioactive material need not be water-soluble as it is gradually carried into the environmental tissue by the slightly water-soluble solvent in a dissolved or micro-dispersed manner.

Generally, any bioactive material can be applied in the liquid composition of the present invention. Representative bioactive materials applicable in the injectable sustained release compositions of the present invention encompass human as well as animal drugs, such as peptide drugs, protein drugs, desensitizing agents, antigens, vaccines, anti-infectives, antibiotics, antimicrobials, antiallergenics, steroidal anti-inflammatory agents, decongestants, miotics, anticholinergics, sympathomimetics, sedatives, hypnotics, psychic energizers, tranquilizers, androgenic steroids, estrogens, progestational agents, humoral agents, prostaglandins, analgesics, antispasmodics, antimalarials, antihistamines, cardioactive agents, non-steroidal anti-inflammatory agents, antiparkinsonian agents, antihypertensive agents, p-adrenergic blocking agents, nutritional agents, benzophenanthridine alkaloids, acaricides and insecticides. To those skilled in the art, other drugs or bioactive materials that can be released in an aqueous environment can be utilized in the described injectable system. Also, various forms of the drugs or bioactive materials may be used. These include without limitation forms such as uncharged molecules, molecular complexes salts, ethers , esters, amides, etc., which are biologically activated when injected into the body, The bioactive material can be miscible in the polymer, organic solvent and/or adjuvant to provide a homogeneous mixture with the polymer, or insoluble in the polymer, organic solvent and/or adjuvant to form a suspension or dispersion in the composition. Preferably, the bioactive material is dissolved in the liquid composition.

The polymer system is formulated in a manner as to contain the bioactive material in an amount effective to provide the desired biological, physiological and/or therapeutic effect. The "effective amount" of a bioactive material incorporated into the polymeric composition depends on various factors, such as the desired release profile, the concentration of bioactive material required for a desired biological effect, and the period of time over which the bioactive material needs to be released for a specific treatment. Ultimately, this amount 554904 PCT/EP2005/0i3377 is determined by the human or animal patient's physician or veterinarian, respectively, who will apply his experience and knowledge in prescribing the appropriate amount of bioactive material for a successful treatment. Generally, the critical upper limit on the amount of bioactive material incorporated into the polymer composition is defined by the maximum peak of the initial burst release, which could cause toxic side effects, and by the need of an acceptable solution or dispersion viscosity for injection through a syringe needle. The lower limit of drug incorporated into the delivery system is only dependent on the activity of the drug and the length of time needed for treatment.

When the liquid composition is injected into soft tissue to provide a sustained release implant, the resulting polymer system will both release the bioactive material and biodegrade as designed so that no residue remains. With certain drugs, the polymer system will degrade after the drug has been completely released. In other cases, the drug will be released only after the polymer system has degraded to a point where the retained drug has been exposed to the body fluids.

The following examples are set forth as representative specific and preferred embodiments of the present invention. These examples are not to be construed as limiting the scope of the invention in any manner. It should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention. The bioactive ingredient used in the examples is a mixture of two compounds of formula where R is hydrogen and methyl, respectively, in a 1 :4 - proportion.

Example 1: Preparation of formulations Under aseptic conditions, a quantity of the thermoplastic polymer and the organic solvent is weighed into a beaker and stirred at 300 rpm for about 12 hours at about 60°C until the polymer is completely dissolved. The mixture is then cooled to room temperature, the bioactive agent added and the suspension gently stirred at 100 rpm until the bioactive agent is completely dissolved. If additionally a water-soluble adjuvant is used, the bioactive agent is OH 554904 P(l7F.P2005/013377 first triturated in the adjuvant and then added. The final formulation is then filled into a syringe of 2 ml content. The composition of six test formulations are tabulated in table 1.

Table 1: Composition [mg/ml] of sustained-release injectable formulations Formulation Bioactive ingredient1 Thermoplastic polymer2 Solvent3 Adjuvant; Ethanol Adjuvant: Glycerol formal Adjuvant: Glycerol A 200 200 799 - - - B 200 150 845 - - - C 200 200 653 100 - - D 200 150 698 100 - - E 200 200 702 F 200 200 705 - - 100 1 Compound of formula I 2 Polylactic acid (PLA) 3 Glycerol triacetate (triacetin) 554904 Example 2: in-vivo Experiments on Beagle dogs The following in-vivo experiments are carried out on six pairs of healthy Beagle dogs of various age, breed, body weight and sex. Each formulation is tested in two dogs, each dog receiving one injection with the active agent and a corresponding placebo, wherein the active agent is replaced by an additional amount of the organic solvent. The active-agent formulations are administered subcutaneously behind the shoulder and over the ribs of the left side. The same volume of placebo solution is injected subcutaneously on the right side of the same animal. The total injection volume per formulation is 2 ml. Consequently, the total amount of active agent per dog is 400 mg, corresponding to a dose of about 40 to about 44 mg/kg of active agent, depending on the body weight of the selected dog.

Blood samples are collected from the vena jugularis of each dog into sterile tubes of about 2.7 ml volume containing EDTA as anticoagulant. Blood is collected at pre-test time and at 2 h, 4 h, 6 h, 8 h, 10 h and 24 h, then at day 2, 4, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, 42 and 45, finally continued biweekly until up to 462 days after administration of the test formulations. The blood samples are kept frozen until LC-MS analysis.

In table 2 the blood levels over time for the formulations A - F are listed. The third column of this table shows that addition of the adjuvants ethanol, glycerol formal or glycerol (formulations C, D, E and F) decreases the maximum blood level reached a few days after injection.

Claims (15)

WO 2006/063794 554904 PCT/EP2005/013377 - 11 - Table 2: Blood ievel [ng/ml] of compound of formula I in adult Beagle dogs after injection Formulation Dog no. Maximum (days after injection) 50 days 100 days 200 days 400 days A 1 89.2 (2) 8.2 7.6 3.5 4.1 A 2 87.6 (2) 44.7 32.1 5.7 5.9 B 3 92.7 (2) 27.4 26.2 26.7 5.6 B 4 117.2(13) 21 15.3 7.4 8.9 C 5 44.2 (3) 2.4 3.3 9.8 14 C 6 47.5 (4) 5.4 4.2 2.6 1.9 D 7 61.2 (1) 7.1 3.8 2.1 - D 8 48.9 (2) 10.1 4.8 3.1 - E 9 35.6 (2) 4.9 2.8 1.9 3.0 E 10 37.4 (6) 11.5 7.4 3.7 3.4 F 11 35.0 (2) 3.3 2.6 1.0 1.8 F 12 40.6 (2) 2.2 2.5 2.0 2.4 354&4 What is claimed is

1. A composition for forming a solid implant in situ within a body by exposure to body fluids, suitable for a controlled release of bioactive material, comprising (i) a biologically active agent, (ii) 10 to 25% by weight of the total composition of a pharmaceutically acceptable, biodegradable, thermoplastic polymer, which is a polylactide which is insoluble in aqueous media or human or animal body fluids, (iii) 50 to 80% by weight of the total composition of a pharmaceutically acceptable, biodegradable, water-insoluble or slightly water-soluble organic solvent, which is a triester of glycerin, and (iv) above 0 to up to 10% by weight of the total composition a pharmaceutically acceptable, water-soluble and biocompatible adjuvant selected from the group consisting of C2-C6alkanols, polyhydroxy alcohols and ketals.

2. A composition according to claim 1, wherein the amount of said thermoplastic polymer (ii) is between about 15% and about 20% and the amount of said solvent (iii) is between about 55% and about 66% by weight of the composition.

3. A composition according to claim 1 or 2, wherein the thermoplastic polymer (ii) is a polylactic acid.

4. A composition according to any one of claims 1 to 3, wherein the solvent (iii) is glycerol triacetate.

5. A composition according to any one of claims 1 to 4, wherein the adjuvant is selected from the group consisting of ethanol, glycerol and glycerol formal.

6. A composition according to any one of claims 1 to 5, wherein the biologically active agent is an acaricide or insecticide.

7. A composition according to any one of claims 1 to 5, wherein the biologically active agent is a compound of formula 554^34" O N H R OH where R is hydrogen and methyl, respectively, in a 1 : 4 - proportion.

8. A composition according to claim 1, wherein the biologically active agent is an animal drug, the thermoplastic polymer is a polylactic acid, the solvent is glycerol triacetate, and the adjuvant is ethanol.

9. A composition according to claim 7, wherein the biologically active agent is an acaricide or insecticide.

10. An implant for the slow release of drugs in a human or animal body, wherein said implant is adapted to be formed in situ within said body by exposure of a composition according to any one of claims 1 to 9 to the fluids of said body.

11. A method of implanting a composition according to any one of claims 1 to 9 in a non-human animal body, wherein said composition is injected into the tissue of said body, therein forming a solid implant on contact with said body's fluids.

12. A composition according to claim 1, substantially as herein described with reference to any one of the Examples thereof.

13. A composition according to any one of claims 1 to 9, substantially as herein described.

14. An implant according to claim 10, substantially as herein described.

15. A method according to claim 11, substantially as herein described.